1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material: Amlodipine Besylate Tablets
2.5 mg, 5 mg and 10 mg

Manufacturer: Lupin Limited
Mumbai 400 098 INDIA

Distributor: Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients | CAS | Quantity
--- | --- | ---
Amlodipine Besylate equivalent to Amlodipine | 88150-42-9 | 2.5 mg/tablet; 5 mg/tablet; 10 mg/tablet
Non-hazardous ingredients | -------- | q.s.

3. HAZARDOUS IDENTIFICATION

Fire and Explosion: Assume that this product is capable of sustaining combustion.

Health: Exposure might occur via skin; eyes; ingestion; inhalation.
May cause sensitisation by inhalation or skin contact.
Harmful if swallowed.
Antihypertensive drug: Has blood pressure lowering properties.

Environment: No information is available about the potential of this product to produce adverse environmental effects.
4. FIRST AID MEASURES

Ingestion

Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation

Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact

Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact

Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia.

If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output.

Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.

Antidotes

No specific antidote exists.
5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards  
Assume that this product is capable of sustaining combustion.

Extinguishing Media  
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures  
For single units (packages): No special requirements needed.  
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous Combustion Products  
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions  
Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions  
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods  
Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling  
No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

Storage  
Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Protect from light.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
9. PHYSICAL & CHEMICAL PROPERTIES

Physical Form
- 2.5 mg: White to off-white, diamond shaped tablets
- 5 mg: White to off-white, elongated octagonal tablets
- 10 mg: White to off-white, round tablets

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Oral Toxicity: Not expected to be toxic following ingestion of recommended maximum daily dose.

Inhalation Toxicity: Can produce respiratory irritation. Adverse effects might occur following inhalation.

Skin Effects: Irritation might occur following direct contact.

Eye Effects: Irritation might occur following direct contact with eyes.

Gastrointestinal Reactions: Anorexia, constipation, dyspepsia, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia

Subchronic effects: Subchronic toxicity of amlodipine besylate was evaluated in rats at oral doses up to 30 mg/kg/day for three months. Drug-related changes included increased heart and gland weight and were reversed one month after cessation of the treatment. These changes are considered to be the effect of the desired effects of the drug, however, they are considered potential hazards in the workplace.

Genetic Toxicity: Not expected to be genotoxic based on animal studies.

Carcinogenicity: Not expected to be carcinogenic based on animal studies.

Reproductive Effects: Not expected to produce adverse effects on fertility or development based on animal studies. No adequate and well-controlled studies in pregnant women. No studies during labor and delivery. Should be used during pregnancy only if clearly needed.

Pharmacological Effects: This material is a calcium channel blocker. It is antianginal and antihypertensive.
12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

The Material Safety Data Sheet (MSDS) should accompany all shipments for reference in the event of spillage or accidental release. Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labeling for air, maritime, or ground transport purposes.

15. REGULATORY INFORMATION

No information found.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.